# Procter Gamble (NSE: PGHH) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/PGHH · Pivot · prices to 22 Oct 2026

Procter Gamble (NSE: PGHH) closed at ₹6,856.00 on 22 Oct 2026, down 0.36% on the day. With a market capitalisation of ₹22,255 Cr, it ranks 331st by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Household & Personal Products.

At its last close the stock traded at 26× trailing earnings, against a return on equity of 62.3% in FY26. Over the past year the share price has fallen 51.5%. Its 52-week range is ₹6,579.00 (1 Oct 2026) to ₹13,903.00 (23 Oct 2025); the last close is 50.7% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹890 Cr (−4.8% year on year) and net profit ₹126 Cr (−34.3%), on a standalone basis. Promoters held 70.64% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹6,856.00 |
| Market cap | ₹22,255 Cr |
| P/E (trailing) | 26 |
| ROE | 62.3% (FY26) |
| ROCE | 76.8% (FY26) |
| Debt to equity | 0 |
| 52-week high | ₹13,903.00 (23 Oct 2025) |
| 52-week low | ₹6,579.00 (1 Oct 2026) |
| 1-year return | −51.5% |

## Quarterly results (₹ crore, standalone)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹890 Cr | −4.8% | ₹126 Cr | −34.3% | ₹38.90 |
| Q4 FY26 | ₹941 Cr | −4.8% | ₹153 Cr | −1.9% | ₹47.17 |
| Q3 FY26 | ₹1,260 Cr | +1.1% | ₹301 Cr | +12.2% | ₹92.87 |
| Q2 FY26 | ₹1,149 Cr | +1.2% | ₹210 Cr | −1.0% | ₹64.65 |
| Q1 FY26 | ₹935 Cr | +0.4% | ₹192 Cr | +136.9% | ₹59.17 |
| Q4 FY25 | ₹989 Cr | −1.3% | ₹156 Cr | +1.1% | ₹48.09 |
| Q3 FY25 | ₹1,246 Cr | +10.2% | ₹269 Cr | +17.3% | ₹82.74 |
| Q2 FY25 | ₹1,135 Cr | +0.0% | ₹212 Cr | +0.6% | ₹65.28 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹934 Cr | ₹234 Cr |
| FY25 | ₹1,151 Cr | ₹201 Cr |
| FY24 | ₹1,230 Cr | ₹229 Cr |
| FY23 | ₹1,114 Cr | ₹193 Cr |
| FY22 | ₹1,009 Cr | ₹177 Cr |
| FY21 | ₹1,356 Cr | ₹254 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 70.64%
- Foreign institutions: 0.98%
- Domestic institutions: 15.59%
- Non-institutions: 12.80%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Neuland Laboratories](https://app.pivotnow.in/stock/NEULANDLAB) | ₹18,855.00 | ₹24,191 Cr | 66.3 | — |
| [Rubicon Research](https://app.pivotnow.in/stock/RUBICON) | ₹1,408.90 | ₹23,301 Cr | 92.3 | — |
| [Piramal Phytoca](https://app.pivotnow.in/stock/PIRPHYTO) | — | ₹21,083 Cr | — | — |
| [SAGILITY](https://app.pivotnow.in/stock/SAGILITY) | ₹44.78 | ₹20,963 Cr | 22.6 | — |
| [Granules India](https://app.pivotnow.in/stock/GRANULES) | ₹807.65 | ₹20,013 Cr | 33 | — |
| [Indraprastha](https://app.pivotnow.in/stock/IGL) | ₹141.87 | ₹19,862 Cr | 12.8 | — |

## Questions and answers

### What is the share price of Procter Gamble today?

Procter Gamble (NSE: PGHH) last closed at ₹6,856.00 on 22 Oct 2026. Its 52-week high is ₹13,903.00 and its 52-week low is ₹6,579.00.

### What is the market cap of Procter Gamble?

Procter Gamble's market capitalisation is ₹22,255 Cr (₹22,255 Cr) at the 22 Oct 2026 close, ranking 331st among the NSE companies Pivot tracks.

### What is the P/E ratio of Procter Gamble?

Procter Gamble trades at a trailing P/E of 26. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 33.

### What is the ROE and ROCE of Procter Gamble?

Return on equity was 62.3% in FY26 and return on capital employed was 76.8% in FY26 (standalone figures).

### Is Procter Gamble a debt-free company?

Procter Gamble is close to debt-free: its debt-to-equity ratio was 0 in FY26.

### What were Procter Gamble's latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), Procter Gamble reported revenue of ₹890 Cr, −4.8% year on year, and net profit of ₹126 Cr, −34.3% year on year.

### How has Procter Gamble stock performed over the last year?

Procter Gamble's share price has fallen 51.5% over the past year, −23.8% over three months and −7.5% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Procter Gamble?

As of 30 Jun 2026: promoters 70.64%, foreign institutions 0.98%, domestic institutions 15.59%, non-institutions 12.80%.

### Who are Procter Gamble's competitors?

The listed Pharma & Healthcare companies closest to Procter Gamble by market cap are Neuland Laboratories, Rubicon Research, Piramal Phytoca, SAGILITY, Granules India and Indraprastha.

### Is Procter Gamble a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Procter Gamble's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on PGHH against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.